课题基金 / 基金详情

Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome

Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
急性肺损伤和急性呼吸窘迫综合征的治疗
批准号：
8328503
负责人：
MICHAEL A. MATTHAY
金额：
$31.72万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
2005
资助国家：
美国
项目状态：
已结题
起止时间：
2005-09-30 至 2011-11-30
来源：
https://reporter.nih.gov/project-details/8328503
关键词：
AcuteAcute Lung InjuryAdultAdult Respiratory Distress SyndromeCaringCharacteristicsClinicalClinical ResearchClinical TrialsClinical Trials Data Monitoring CommitteesConsent FormsCritical IllnessEdemaElectronicsEligibility DeterminationEnrollmentEthicsGenderHypoxemiaIntensive Care UnitsLung InflammationNatural HistoryOutcomePathologyPatientsPharmaceutical PreparationsProceduresProtocols documentationPublicationsResearch PersonnelResourcesRespiratory distressReview CommitteeSamplingSyndromeTeleconferencesVotingbasedata exchangeimprovedmeetingsmembermortalitypatient populationpreventprotocol development

项目摘要

项目成果

MICHAEL A. MATTHAY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Acute lung injury (ALI) and its more severe form, adult respiratory distress (ARD), is a devastating clinical syndrome of sudden lung inflammation that results in severe edema and hypoxemia and requires care in the intensive care unit. Mortality is between 30-40% in controlled settings. To date, no single drug has proven effective for improving mortality in ALI/ARDS despite many large and small clinical trials. The objective of the Clinical Research Network (ARDSNet) is to develop and conduct clinical research trials to prevent, treat, and improve the outcome of patients with acute lung injury, acute respiratory distress syndrome, and possibly other related critical illnesses.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Prevention and Early Treatment of Acute Lung Injury
Allogeneic Human Mesenchymal Stem Cells for the Treatment of Acute Lung Injury
Allogeneic Human Mesenchymal Stem Cells for the Treatment of Acute Lung Injury
Allogeneic Human Mesenchymal Stem Cells for the Treatment of Acute Lung Injury
海外基金